{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:35:22Z","timestamp":1793936122643,"version":"4.8.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Morbidity and mortality due to immunosuppression remain among the foremost clinical challenges in chronic lymphocytic leukemia (CLL). Although immunosuppression is considered to originate within the lymph node (LN) microenvironment, alterations in T and natural killer (NK) cells have almost exclusively been studied in peripheral blood (PB). Whereas chemoimmunotherapy further deteriorates immune function, novel targeted agents like the B-cell lymphoma 2 inhibitor venetoclax potentially spare nonmalignant lymphocytes; however, the effects of venetoclax on nonleukemic cells have not been explored. We address these unresolved issues using a comprehensive analysis of nonmalignant lymphocytes in paired LN and PB samples from untreated CLL patients, and by analyzing the effects of venetoclax-based treatment regimens on the immune system in PB samples from previously untreated and relapsed\/refractory patients. CLL-derived LNs contained twice the amount of suppressive regulatory T cells (Tregs) and CLL supportive follicular T helper (Tfh) cells compared with PB. This was accompanied by a low frequency of cytotoxic lymphocytes. The expression of PD-1 by CD8+ T cells was significantly higher in LN compared with PB. Venetoclax-based treatment led to deep responses in the majority of patients, but also to decreased absolute numbers of B, T, and NK cells. Tfh cell, Treg, and PD-1+ CD8+ T cell numbers were reduced more than fivefold after venetoclax-based therapy, and overproduction of inflammatory cytokines was reduced. Furthermore, we observed restoration of NK cell function. These data support the notion that the immunosuppressive state in CLL is more prominent within the LN. Venetoclax-based regimens reduced the immunosuppressive footprint of CLL, suggesting immune recovery after the elimination of leukemic cells.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000360","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T16:54:07Z","timestamp":1568134447000},"page":"2642-2652","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":109,"title":["Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment"],"prefix":"10.1182","volume":"3","author":[{"given":"Iris","family":"de Weerdt","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"},{"name":"Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hofland","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"},{"name":"Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"de Boer","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"},{"name":"Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A.","family":"Dobber","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dubois","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"van Nieuwenhuize","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"},{"name":"Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Mobasher","sequence":"first","affiliation":[{"name":"Genentech Inc., South San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fransien","family":"de Boer","sequence":"first","affiliation":[{"name":"Internal Medicine, Ikazia Hospital, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mels","family":"Hoogendoorn","sequence":"first","affiliation":[{"name":"Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjo A.","family":"Velders","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van der Klift","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4694-6048","authenticated-orcid":false,"given":"Ester B. M.","family":"Remmerswaal","sequence":"first","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederike J.","family":"Bemelman","sequence":"first","affiliation":[{"name":"Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten U.","family":"Niemann","sequence":"first","affiliation":[{"name":"Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Kersting","sequence":"first","affiliation":[{"name":"Department of Hematology, Haga Hospital, The Hague, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Eldering","sequence":"first","affiliation":[{"name":"Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"},{"name":"Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3253-8759","authenticated-orcid":false,"given":"Sanne H.","family":"Tonino","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"},{"name":"Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, and"},{"name":"Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"issue":"5","key":"2020021316133162800_B1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020021316133162800_B2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"2020021316133162800_B3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2016.142679","article-title":"Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk","volume":"102","author":"van Attekum","year":"2017","journal-title":"Haematologica"},{"issue":"13","key":"2020021316133162800_B4","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2020021316133162800_B5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood-2003-01-0182","article-title":"Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia","volume":"102","author":"Mackus","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2020021316133162800_B6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2141.1997.d01-2107.x","article-title":"Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells","volume":"96","author":"Mu","year":"1997","journal-title":"Br J Haematol"},{"issue":"17","key":"2020021316133162800_B7","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1182\/blood-2012-11-467670","article-title":"IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells","volume":"122","author":"Pascutti","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020021316133162800_B8","doi-asserted-by":"crossref","first-page":"e1371399","DOI":"10.1080\/2162402X.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2017","journal-title":"OncoImmunology"},{"issue":"1","key":"2020021316133162800_B9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/leu.2015.174","article-title":"The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells","volume":"30","author":"Saulep-Easton","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2020021316133162800_B10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020021316133162800_B11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0318-3","article-title":"PI3K\u03b4 inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia","volume":"33","author":"Hanna","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"2020021316133162800_B12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D\u2019Arena","year":"2011","journal-title":"Leuk Res"},{"issue":"7","key":"2020021316133162800_B13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"2020021316133162800_B14","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"7","key":"2020021316133162800_B15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2020021316133162800_B16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"42","key":"2020021316133162800_B17","doi-asserted-by":"crossref","first-page":"68513","DOI":"10.18632\/oncotarget.12097","article-title":"NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma","volume":"7","author":"Parry","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"2020021316133162800_B18","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"OncoImmunology"},{"key":"2020021316133162800_B19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/asheducation-2014.1.163","article-title":"Indolent lymphoma: follicular lymphoma and the microenvironment-insights from gene expression profiling","volume":"2014","author":"Rimsza","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2020021316133162800_B20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2020021316133162800_B21","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2010.89","article-title":"Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy","volume":"24","author":"Ysebaert","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"2020021316133162800_B22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1080\/10428194.2018.1457147","article-title":"Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia","volume":"59","author":"Pleyer","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2020021316133162800_B23","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020021316133162800_B24","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2020021316133162800_B25","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","article-title":"Myeloid-derived suppressor cells express Bruton\u2019s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment","volume":"76","author":"Stiff","year":"2016","journal-title":"Cancer Res"},{"issue":"15","key":"2020021316133162800_B26","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2020021316133162800_B27","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"4","key":"2020021316133162800_B28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2020021316133162800_B29","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"2020021316133162800_B30","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/bloodadvances.2018019422","article-title":"Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL","volume":"2","author":"Kater","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2020021316133162800_B31","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2020021316133162800_B32","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia","volume":"133","author":"Flinn","year":"2019","journal-title":"Blood"},{"key":"2020021316133162800_B33","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3389\/fimmu.2017.01809","article-title":"Life and death of activated T cells: how are they different from na\u00efve T cells?","volume":"8","author":"Zhan","year":"2017","journal-title":"Front Immunol"},{"issue":"5","key":"2020021316133162800_B34","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/cdd.2017.30","article-title":"Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo","volume":"24","author":"Carrington","year":"2017","journal-title":"Cell Death Differ"},{"issue":"6","key":"2020021316133162800_B35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev"},{"issue":"5","key":"2020021316133162800_B36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev"},{"issue":"7","key":"2020021316133162800_B37","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood-2011-09-381574","article-title":"Human virus-specific effector-type T cells accumulate in blood but not in lymph nodes","volume":"119","author":"Remmerswaal","year":"2012","journal-title":"Blood"},{"issue":"13","key":"2020021316133162800_B38","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","article-title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches","volume":"112","author":"Hallaert","year":"2008","journal-title":"Blood"},{"key":"2020021316133162800_B39","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2018.01990","article-title":"Positive and negative roles of innate effector cells in controlling cancer progression","volume":"9","author":"Stolk","year":"2018","journal-title":"Front Immunol"},{"issue":"19","key":"2020021316133162800_B40","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/blood-2010-09-303057","article-title":"Dissecting CD56dim human NK cells","volume":"116","author":"Moretta","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020021316133162800_B41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/imr.12747","article-title":"TFH cells in bystander and cognate interactions with B cells","volume":"288","author":"Wan","year":"2019","journal-title":"Immunol Rev"},{"issue":"6","key":"2020021316133162800_B42","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1007\/s13277-013-0937-2","article-title":"Association of peripheral CD4+ CXCR5+ T cells with chronic lymphocytic leukemia","volume":"34","author":"Cha","year":"2013","journal-title":"Tumour Biol"},{"issue":"11","key":"2020021316133162800_B44","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur J Immunol"},{"issue":"6","key":"2020021316133162800_B45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2017-0147","article-title":"Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia","volume":"10","author":"Garc\u00eda-Mu\u00f1oz","year":"2018","journal-title":"Immunotherapy"},{"issue":"suppl 1","key":"2020021316133162800_B46","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2018-186","article-title":"Combined ibrutinib and venetoclax in patients with treatment-na\u00efve high-risk chronic lymphocytic leukemia (CLL)","volume":"132","author":"Jain","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2020021316133162800_B47","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2020021316133162800_B48","first-page":"4481","article-title":"Ibrutinib inhibits cGVHD pathogenic pre-germinal cnter B-cells and follicular helper cells while preserving immune memory and Th1 T-cells","volume":"130","author":"Sahaf","year":"2017","journal-title":"Blood"},{"issue":"1 suppl","key":"2020021316133162800_B49","doi-asserted-by":"crossref","first-page":"166.28","DOI":"10.4049\/jimmunol.200.Supp.166.28","article-title":"Abnormal T follicular helper cell subsets in chronic lymphocytic leukemia","volume":"200","author":"Marshall","year":"2018","journal-title":"J Immunol."},{"issue":"2","key":"2020021316133162800_B50","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2020021316133162800_B51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/leu.2017.11","article-title":"Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood","volume":"31","author":"Herndon","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2020021316133162800_B52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2016-01-683128","article-title":"Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration","volume":"128","author":"Pasikowska","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020021316133162800_B53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/14653249.2011.553595","article-title":"Human V\u03b41 \u03b3\u03b4 T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells","volume":"13","author":"Siegers","year":"2011","journal-title":"Cytotherapy"},{"issue":"21","key":"2020021316133162800_B54","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020021316133162800_B55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3109\/10428194.2012.728287","article-title":"Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias","volume":"54","author":"Lad","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020021316133162800_B56","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020021316133162800_B57","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol"},{"issue":"5","key":"2020021316133162800_B58","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/10428190902803677","article-title":"Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020021316133162800_B59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1158\/1078-0432.CCR-14-3017","article-title":"Antigen selection shapes the T-cell repertoire in chronic lymphocytic leukemia","volume":"22","author":"Vardi","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2020021316133162800_B60","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020021316133162800_B61","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/sji.12331","article-title":"CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia","volume":"82","author":"Lorentzen","year":"2015","journal-title":"Scand J Immunol"},{"issue":"26","key":"2020021316133162800_B62","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020021316133162800_B63","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jcyt.2016.07.003","article-title":"Review: current clinical applications of chimeric antigen receptor (CAR) modified T cells","volume":"18","author":"Geyer","year":"2016","journal-title":"Cytotherapy"},{"issue":"303","key":"2020021316133162800_B64","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/17\/2642\/1716326\/advancesadv2019000360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/17\/2642\/1716326\/advancesadv2019000360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T23:16:13Z","timestamp":1695165373000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/17\/2642\/261387\/Distinct-immune-composition-in-lymph-node-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":63,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000360","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]}}}